IL323792A - New treatment for SMA - Google Patents
New treatment for SMAInfo
- Publication number
- IL323792A IL323792A IL323792A IL32379225A IL323792A IL 323792 A IL323792 A IL 323792A IL 323792 A IL323792 A IL 323792A IL 32379225 A IL32379225 A IL 32379225A IL 323792 A IL323792 A IL 323792A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- dimethylimidazo
- diazaspiro
- octan
- pyridazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- External Artificial Organs (AREA)
Claims (18)
1. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA) at 0.25 mg/kg for patients with a body weight of less than 20kg.
2. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to claim 1, in patient in need thereof, wherein the patient is a human.
3. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to claim 1 or 2, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one is orally administered.
4. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 3, wherein the patient is a human, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one is being administered orally at 0.25mg/kg for patients with a body weight of less than 20kg.
5. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 4, wherein SMA is type II SMA.
6. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 5, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one is administered once a day.
7. A pharmaceutical composition for use in the treatment of SMA, at 0.25 mg per kilogram of body weight of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2- b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for patients with a body weight of less than 20kg, being administered, in particular orally administered once a day, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof formulated as oral aqueous solution by dissolving 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof in a buffer system at pH of less than pH 4, in order to provide sufficiently high drug concentration, - 73 - e.g. citric buffer system, malate buffer system, maleate buffer system, or tartrate buffer system.
8. The pharmaceutical composition for use according to claim 7, wherein the buffer system is at pH 3.0 to 3.2.
9. The pharmaceutical composition for use according to claim 7, wherein the buffer system is tartrate buffer system.
10. The pharmaceutical composition for use according to any one of claims 7 to 9, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof as a dry powder or granulation for constitution of an oral solution.
11. The pharmaceutical composition for use according to any one of claims 7 to 10, wherein a buffer system can be incorporated into dry formulation by the selection of organic acid and salts thereof as fine powders, e.g. tribasic sodium citrate and citric acid, disodium malate and malic acid, potassium sodium tartrate and tartaric acid, or disodium tartrate and tartaric acid.
12. The pharmaceutical composition for use according to any one of claims 7 to 10, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof, a diluent, such as sorbitol, isomalt, or mannitol, and combinations thereof, which ensure fast dissolution of the powder blend during constitution of the oral solution and optionally, filler can be added to be granulated by dry compaction in order to improve the flowability and to ensure robust uniformity.
13. The pharmaceutical composition for use according to any one of claims 7 to 12, wherein the pharmaceutical composition comprises: 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; and tartaric acid.
14. The pharmaceutical composition for use according to any one of claims 7 to 13, wherein the pharmaceutical composition comprises: 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; - 74 - tartaric acid; and mannitol or a mixture of mannitol and isomalt.
15. The pharmaceutical composition for use according to any one of claims 7 to 14, wherein the pharmaceutical composition comprises: 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; and mannitol or a mixture of mannitol and isomalt.
16. The pharmaceutical composition for use according to any one of claims 7 to 15, wherein the pharmaceutical composition comprises: 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; tartaric acid; ascorbic acid; and disodium edetate.
17. The pharmaceutical composition for use according to any one of claims 7 to 16, wherein the pharmaceutical composition comprises: 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; tartaric acid; mannitol or a mixture of mannitol and isomalt; ascorbic acid; and disodium edetate.
18. The pharmaceutical composition for use according to any one of claims 7 to 12, wherein the pharmaceutical composition comprises: - 75 - 1 to 10 %wt of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; 5 to 15 %wt of a buffer system, particularly a buffer system selected from citrate, malate, maleate or tartrate, more particularly malate or tartrate, most particularly tartrate; or alternatively the corresponding acid of a buffer system alone as acidifier, particularly tartaric acid; 40 to 70 %wt of a diluent, particularly mannitol or a mixture of mannitol and isomalt, more particularly mannitol; 1 to 4 %wt of an antioxidant, particularly ascorbic acid; 0.5 to 2 %wt of a stabilizer, particularly disodium edetate; 0.5 to 2 %w of a lubricant, particularly PEG6000; 0 to 3 %wt of a sweetener, particularly sucralose or sodium saccharin, most particularly sucralose; and 0 to 20 %wt of a flavor, particularly strawberry flavor or vanilla flavor; wherein the total amount of ingredients does not exceed 100 %wt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17194520 | 2017-10-03 | ||
| PCT/EP2018/076577 WO2019068604A1 (en) | 2017-10-03 | 2018-10-01 | New treatment of sma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323792A true IL323792A (en) | 2025-12-01 |
Family
ID=60019743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273543A IL273543B2 (en) | 2017-10-03 | 2018-10-01 | New treatment of sma |
| IL323792A IL323792A (en) | 2017-10-03 | 2018-10-01 | New treatment for SMA |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273543A IL273543B2 (en) | 2017-10-03 | 2018-10-01 | New treatment of sma |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11534444B2 (en) |
| EP (2) | EP3691647B1 (en) |
| JP (3) | JP7423515B2 (en) |
| KR (1) | KR102761837B1 (en) |
| CN (2) | CN111182900A (en) |
| AU (2) | AU2018344402B2 (en) |
| CA (1) | CA3078137A1 (en) |
| ES (1) | ES3072590T3 (en) |
| IL (2) | IL273543B2 (en) |
| MX (2) | MX2020003416A (en) |
| TW (1) | TWI870340B (en) |
| WO (1) | WO2019068604A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3072590T3 (en) * | 2017-10-03 | 2026-07-02 | Hoffmann La Roche | New treatment of sma |
| WO2020249577A1 (en) * | 2019-06-12 | 2020-12-17 | F. Hoffmann-La Roche Ag | New treatment of sma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| AU2015261046C1 (en) | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| MX375925B (en) * | 2014-06-25 | 2025-03-07 | Hoffmann La Roche | IMIDAZO[1,2-A]PYRAZIN-1-YL-BENZAMIDE COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY. |
| AR106652A1 (en) * | 2015-11-12 | 2018-02-07 | Hoffmann La Roche | COMPOUNDS TO TREAT AMIOTROPHIC LATERAL SCLEROSIS |
| AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| ES3072590T3 (en) * | 2017-10-03 | 2026-07-02 | Hoffmann La Roche | New treatment of sma |
-
2018
- 2018-10-01 ES ES18789010T patent/ES3072590T3/en active Active
- 2018-10-01 JP JP2020519035A patent/JP7423515B2/en active Active
- 2018-10-01 MX MX2020003416A patent/MX2020003416A/en unknown
- 2018-10-01 KR KR1020207012316A patent/KR102761837B1/en active Active
- 2018-10-01 WO PCT/EP2018/076577 patent/WO2019068604A1/en not_active Ceased
- 2018-10-01 AU AU2018344402A patent/AU2018344402B2/en active Active
- 2018-10-01 CN CN201880065062.7A patent/CN111182900A/en active Pending
- 2018-10-01 EP EP18789010.8A patent/EP3691647B1/en active Active
- 2018-10-01 EP EP26166118.5A patent/EP4755451A3/en active Pending
- 2018-10-01 CA CA3078137A patent/CA3078137A1/en active Pending
- 2018-10-01 IL IL273543A patent/IL273543B2/en unknown
- 2018-10-01 IL IL323792A patent/IL323792A/en unknown
- 2018-10-01 CN CN202311841266.4A patent/CN117919251A/en active Pending
- 2018-10-02 TW TW107134794A patent/TWI870340B/en active
-
2020
- 2020-04-02 US US16/838,942 patent/US11534444B2/en active Active
- 2020-07-13 MX MX2023004924A patent/MX2023004924A/en unknown
-
2022
- 2022-12-05 US US18/061,985 patent/US12350273B2/en active Active
-
2024
- 2024-01-17 JP JP2024005144A patent/JP7481593B2/en active Active
- 2024-04-25 JP JP2024071255A patent/JP2024102152A/en active Pending
- 2024-11-22 AU AU2024266812A patent/AU2024266812A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4755451A3 (en) | 2026-08-19 |
| IL273543B1 (en) | 2025-12-01 |
| US11534444B2 (en) | 2022-12-27 |
| KR20200065025A (en) | 2020-06-08 |
| JP2020536090A (en) | 2020-12-10 |
| JP2024041949A (en) | 2024-03-27 |
| EP3691647C0 (en) | 2026-05-27 |
| AU2018344402B2 (en) | 2024-08-29 |
| EP3691647A1 (en) | 2020-08-12 |
| IL273543A (en) | 2020-05-31 |
| EP4755451A2 (en) | 2026-06-10 |
| JP7423515B2 (en) | 2024-01-29 |
| EP3691647B1 (en) | 2026-05-27 |
| MX2020003416A (en) | 2020-07-20 |
| US20200375993A1 (en) | 2020-12-03 |
| TWI870340B (en) | 2025-01-21 |
| AU2018344402A1 (en) | 2020-04-09 |
| WO2019068604A1 (en) | 2019-04-11 |
| JP2024102152A (en) | 2024-07-30 |
| IL273543B2 (en) | 2026-04-01 |
| MX2023004924A (en) | 2023-05-17 |
| TW201924684A (en) | 2019-07-01 |
| ES3072590T3 (en) | 2026-07-02 |
| AU2024266812A1 (en) | 2024-12-12 |
| KR102761837B1 (en) | 2025-02-05 |
| CN117919251A (en) | 2024-04-26 |
| CA3078137A1 (en) | 2019-04-11 |
| US12350273B2 (en) | 2025-07-08 |
| CN111182900A (en) | 2020-05-19 |
| US20230338382A1 (en) | 2023-10-26 |
| JP7481593B2 (en) | 2024-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12396947B2 (en) | Methotrexate composition | |
| EP1200091B1 (en) | Pharmaceutical composition comprising tadalafil | |
| ES2391912T3 (en) | Valganciclovir powder formulation | |
| EP3003384B1 (en) | Oral solution comprising atomoxetine hydrochloride | |
| WO2016159897A1 (en) | Potassium citrate suspension | |
| WO2011014248A1 (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| KR20150002453A (en) | Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof | |
| WO2011136751A2 (en) | Water soluble pharmaceutical composition | |
| JP2022536669A5 (en) | ||
| IL273543B1 (en) | New treatment for SMA | |
| EP2566448B1 (en) | Efervescent formulations comprising cefdinir | |
| KR101634382B1 (en) | Oral liquid formulation of tadalafil | |
| EP2528593A2 (en) | Effervescent formulations comprising cefprozil as active agent | |
| EP1651191A2 (en) | Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use | |
| WO2006129160A2 (en) | Stable aqueous oral solution of risperidone | |
| WO2013109230A1 (en) | Pharmaceutical compositions comprising tadalafil | |
| RU2011140785A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TYPE 2 DIABETES | |
| EP3678498B1 (en) | Composition for calcium supplementation | |
| EP3678497B1 (en) | Composition for calcium supplementation | |
| KR101638452B1 (en) | Sildenafil-Bentonite-AEA Nanohybrid, Pharmaceutical Composition Containing the Same and Method for Preparing the Same | |
| ES2406757T3 (en) | Orodispersible tablet containing a sildenafil salt | |
| WO2014027973A1 (en) | Paliperidone oral solution | |
| US20230082870A1 (en) | Composition for calcium supplementation | |
| KR20160012921A (en) | Oral fast dissolving formulation containing blonanserin | |
| CN104352461A (en) | Oral pharmaceutical preparation of tadalafil |